[1]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247-252.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
　Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(04):247-252.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
点击复制

硒治疗自身免疫性甲状腺疾病的荟萃分析()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年04期
页码:
247-252
栏目:
荟萃分析
出版日期:
2016-07-20

文章信息/Info

Title:
A meta-analysis of selenium in the treatment of autoimmune thyroid diseases
作者:
房方; 卫红艳; 王坤玲; 朱梅
300052 天津医科大学总医院内分泌科
Author(s):
Fang Fang;  Wei Hongyan;  Wang Kunling;  Zhu Mei
Department of Endocrinology, The General Hospital, Tianjin Medical University,Tianjin 300052, China
关键词:
硒;  自身免疫性甲状腺疾病;  桥本甲状腺炎;  Graves病
Keywords:
Selenium;  Autoimmune thyroid disease;  Hashimoto's thyroiditis;  Graves' disease
DOI:
10.3760/cma.j.issn.1673-4157.2016.04.09
摘要:
目的 评价元素硒治疗自身免疫性甲状腺疾病(AITD)的有效性和安全性。方法 通过5个数据库(MEDLINE,Cochrane Central Register of Controlled Trials,中国期刊全文数据库,中国生物医学文献数据库和维普数据库)检索所有研究元素硒治疗AITD的随机对照试验(RCT)。由两名研究者独立筛选文献、提取数据和进行结果的统计分析。将结果数据形式一致的同类临床试验的结果进行荟萃分析,对不能荟萃分析的数据进行描述性分析。共纳入30项RCT,涉及2 963例AITD患者。结果(1)与对照组相比,硒治疗组桥本甲状腺炎患者甲状腺过氧化物酶抗体(TPOAb)和甲状腺球蛋白抗体(TgAb)水平明显下降[标准化均数差(SMD)=-1.35, 95% CI: -1.93～-0.67, P<0.000 01和SMD=-0.92,95% CI: -1.53～-0.31, P<0.01]。(2)硒治疗组与对照组相比,Graves病患者促甲状腺激素受体抗体(TRAb)水平降低(均数差=-2.5,95%CI:-2.99～-2.01, P<0.000 01)。(3)元素硒可以降低Graves病患者血清游离T3(FT3)和游离T4(FT4)水平(均数差=-1.57,95%CI: -2.56～ -0.58,P<0.001和均数差=-3.74,95% CI: -5.65～ -1.82, P=0.000 01),但对桥本甲状腺炎患者FT3、FT4和促甲状腺激素的作用不明显(P均>0.05)。结论 对AITD患者使用200 μg/d的元素硒治疗3～12个月,能够有效降低抗甲状腺自身抗体(TPOAb, TgAb和TRAb)的水平,并具有较好的安全性。
Abstract:
Objective To assess the effectiveness and safety of selenium in the treatment of autoimmune thyroid diseases(AITD). Methods Five databases(MEDLINE, Cochrane Central Register of Controlled Trials, CBM, CNKI and VIP)were searched for all randomized controlled trial(RCT)which investigating the effectiveness of selenium in the treatment of AITD. Two authors independently selected studies, extracted data and analyzed the results. Meta-analyses were performed when more than one study with sufficient similarity provided data on an outcome. Thirty RCTs were included involving 2 963 patients with AITD. Results(1)Compared with control group, serum thyroid peroxidase antibody(TPOAb)and thyroglobulin antibody(TgAb)were reduced in patients with Hashimoto's thyroiditis treated with selenium[standardized mean difference(SMD)=-1.35(95% CI:-1.93 to -0.67, P<0.000 01), -0.92(95% CI:-1.53 to -0.31, P<0.01), respectively].(2)Compared with control group, the concentration of thyrotropin receptor antibody(TRAb)was significantly decreased in patients of Graves' disease treated with selenium [mean difference(MD)=-2.5, 95% CI -2.99 to -2.01, P<0.000 01].(3)Serum concentrations of free T3(FT3)and free T4(FT4)were significantly reduced in patients of Graves' disease treated with selenium(MD=-1.57, 95% CI:-2.56 to -0.58, P<0.001 and MD=-3.74, 95%CI:-5.65 to -1.86, P=0.000 01), but serum FT3, FT4 and thyroid stimulating hormone in patients of Hashimoto's thyroiditis treated with selenium were not significantly decreased(all P>0.05). Conclusion Selenium supplementation of 200 μg/d for 3 to 12 months in patients with AITD can effectively decrease the concentration of anti-thyroid autoimmune antibodies(including TPOAb, TgAb and TRAb), and have safety profile.

参考文献/References:

[1] Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics[J]. Annu Rev Pathol,2014,9:147-156. DOI: 10.1146/annurev-pathol-012513-104713.
[2] 张怡, 袁卫红. 硒与自身免疫性甲状腺疾病[J]. 国际放射医学核医学杂志, 2012, 36(6):376-379. DOI: 10.3760/cma.j.issn.1673-4114.2012.06.013.
[3] Duntas LH. Selenium and the thyroid: a close-knit connection[J].J Clin Endocrinol Metab,2010,95(12):5180-5188. DOI: 10.1210/jc.2010-0191.
[4] 金晶, 胡耀敏, 刘伟. 硒治疗自身免疫性甲状腺炎的系统评价[J]. 上海交通大学学报(医学版), 2010, 30(11):1356-1360. DOI: 10.3969/j.issn.1674-8115.2010.11.009.
[5] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]. Control Clin Trials, 1996,17(1):1-12.
[6] 朱平, 周冬梅, 李伟. 硒制剂治疗桥本甲状腺炎伴甲减患者30例临床疗效[J]. 中国老年学杂志, 2012, 32(8):1710-1711. DOI: 10.3969/j.issn.1005-9202.2012. 08.082.
[7] Gärtner R, Gasnier BC, Dietrich JW,et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations[J]. J Clin Endocrinol Metab,2002,87(4):1687-1691.
[8] Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis[J].Eur J Endocrinol,2003,148(4):389-393.
[9] Gärtner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis[J].Biofactors,2003,19(3-4):165-170.
[10] 王栋钢, 雷培芸, 杨咏梅, 等. 硒对儿童桥本甲状腺炎的影响[J]. 广东微量元素科学, 2004, 11(2):34-36.
[11] Turker O, Kumanlioglu K, Karapolat I,et al. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses[J].J Endocrinol,2006,190(1):151-156.
[12] Karanikas G, Schuetz M, Kontur S, et al. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis[J].Thyroid,2008,18(1):7-12. DOI: 10.1089/thy.2007.0127.
[13] 颜美珠, 王曙, 缪婕, 等. 硒在桥本甲状腺炎中的作用[J]. 中华内分泌代谢杂志, 2008, 24(2):194-195. DOI:10.3321/J.ISSN.1000-6699.2008.02.026.
[14] Bonfig W, Gärtner R, Schmidt H. Selenium supplementation does not decrease thyroid peroxidase antibody concentration in children and adolescents with autoimmune thyroiditis[J].SciWorld J,2010,10:990-996. DOI: 10.1100/tsw.2010.91.
[15] Nacamulli D, Mian C, Petricca D, et al. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis[J].Clin Endocrinol(Oxf),2010,73(4):535-539. DOI: 10.1111/j.1365-2265.2009.03758.x.
[16] 张洁红, 张彤, 段敏虹, 等. 硒对成人桥本甲状腺炎的影响[J]. 中国实用医刊, 2010, 37(9):40-41. DOI: 10.376/cma.j.issn.1674- 4756.2010.09.018.
[17] Krysiak R, Okopien B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis[J].J Clin Endocrinol Metab,2011,96(7):2206-2215.DOI: 10.1210/jc.2010-2986.
[18] 雷水红, 蔡霞, 李经, 等. 硒联合抑亢丸、甲巯咪唑治疗桥本甲状腺炎性甲亢的疗效观察[J]. 山东医药, 2011, 51(37):88-89.
[19] Anastasilakis AD, Toulis KA, Nisianakis P,et al. Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial[J].Int J Clin Pract,2012,66(4):378-383. DOI: 10.1111/j.1742-1241.2011.02879.x.
[20] Bhuyan AK, Sarma D, Saikia UK. Selenium and the thyroid: a close-knit connection[J].Indian J Endocrinol Metab,2012,16(Suppl 2):S354-S355. DOI: 10.4103/2230-8210.104090.
[21] Krysiak R, Okopien B. Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto's thyroiditis[J].Thromb Haemost,2012,108(5):973-980. DOI: 10.1160/TH12-04-0275.
[22] 薛冀苏, 幸思忠. 补硒治疗对桥本氏甲状腺炎的临床观察研究[J]. 当代医学, 2012, 18(12):90-91. DOI: 10.3969/j.issn.1009-4393.2012.12.062.
[23] 朱琳, 白雪, 腾卫平, 等. 硒对自身免疫性甲状腺炎自身抗体的影响[J]. 中华医学杂志, 2012, 92(32):2256-2260. DOI: 10.3760/cma.j.issn.0376-2491.2012.32.008.
[24] 邓顺有, 陈小燕, 吴琳英, 等. 硒对甲状腺功能正常的桥本甲状腺炎的影响研究[J]. 中国全科医学, 2013, 16(7C):2483-2485. DOI: 10.3969/j. issn.1007-9572.2013.07.089.
[25] 吕飞娟, 杨燕玲, 许景生, 等. 亚硒酸钠治疗桥本甲状腺炎的临床观察[J]. 临床军医杂志, 2013, 41(1):35-41.DOI:10.3969/j.issn.1671-3826.2013.01.018.
[26] 张薇, 王俊芳, 李京丽, 等. 硒对桥本甲状腺炎患者TPOAb及TGAb水平的影响[J]. 中国医学创新, 2013, 10(14):13-14. DOI: 10.3969/j.issn.1674-4985.2013.14.007.
[27] Eskes SA, Endert E, Fliers E,et al. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies[J]. Clin Endocrinol(Oxf),2014,80(3):444-451. DOI: 10.1111/cen.12284.
[28] 姜云生. 硒酵母治疗桥本病100例分析[J]. 吉林医学, 2014, 35(11):2303-2304.
[29] 曾秀琴, 马卫英. 硒酵母降低桥本甲状腺炎相关抗体滴度的疗效观察[J]. 实用糖尿病杂志, 2014, 10(2):57-58.
[30] Claudio M, George JK, Gerasimos EK, et al. Selenium and the course of mild Graves' orbitopathy[J]. N Engl Med, 2011, 364(20):1921-1931.DOI:10.1056/NEJMoa1012985.
[31] 杜映红, 毛睿睿. 硒联合甲巯咪唑治疗Graves'病患者的临床研究[J]. 湖南中医药大学学报, 2013, 33(12):73-108. DOI: 10.3969/j.issn.1674-070X.2013.12.042.073.01.
[32] 王俊芳, 张薇, 李京丽, 等. 硒对Graves'病患者血清TPOAb、TGAb水平的影响[J]. 中西医结合心脑血管病杂志, 2013, 11(4):502-503.DOI:10.3969/j.issn.1672-1349.2013.04.062.
[33] 朱翠颜, 王筱菁, 邓承宗. 硒对弥漫性毒性甲状腺肿自身免疫抗体的影响[J]. 吉林医学, 2013, 34(16):3147-3148.DOI:10.3969/j.issn.1004-0412.2013.16.039.
[34] 黄珊, 谢珊, 冼碧霞. 微量元素硒对弥漫性甲状腺肿的影响及其护理探讨[J]. 海南医学, 2014, 25(10):1546-1547. DOI: 10.3969/j.issn.1003-6350.2014.10.0601.
[35] 赖景雄. 硒酵母片联合甲巯咪唑治疗Graves'病疗效观察[J]. 药物流行病学杂志, 2014, 23(8):472-474.
[36] Toulis KA, Anastasilakis AD, Tzellos TG,et al. Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis[J].Thyroid,2010,20(10):1163-1173. DOI:10.1089/thy.2009.0351.
[37] van Zuuren EJ, Albusta AY, Fedorowicz Z, et al. Selenium supplementation for Hashimoto's thyroiditis[J].Cochrane Database Syst Rev,2013,6:CD010223. DOI: 10.1002/14651858.CD010223.pub2.

相似文献/References:

[1]朱丹,陈国芳,刘超,等.糖尿病患者合并甲状腺功能异常的机制 及其影响[J].国际内分泌代谢杂志,2016,36(03):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
　Zhu Dan*,Chen Guofang,Liu Chao,et al.Mechanisms of diabetes combined with thyroid dysfunction and its influence[J].International Journal of Endocrinology and Metabolism,2016,36(04):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
[2]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
　Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(04):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[3]司马盼盼 孙良阁.多囊卵巢综合征与自身免疫性甲状腺疾病的相关性[J].国际内分泌代谢杂志,2018,38(03):163.[doi:10.3760/cma.j.issn.1673-4157.2018.03.005]
　Sima Panpan,Sun Liangge..Correlation between polycystic ovary syndrome and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2018,38(04):163.[doi:10.3760/cma.j.issn.1673-4157.2018.03.005]
[4]相萍萍 刘超.滤泡辅助性T细胞、滤泡调节性T细胞与自身免疫性 甲状腺疾病[J].国际内分泌代谢杂志,2019,39(03):168.[doi:10.3760/cma.j.issn.1673-4157.2019.03.006]
　Xiang Pingping,Liu Chao.T foliicular helper cells, T follicular regulatory cells and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2019,39(04):168.[doi:10.3760/cma.j.issn.1673-4157.2019.03.006]
[5]杨小颖 唐露霖 尚文斌.表观遗传修饰在自身免疫性甲状腺疾病发病中的作用[J].国际内分泌代谢杂志,2020,40(03):169.[doi:10.3760/cma.j.issn.1673-4157.2020.03.006]
　Yang Xiao-ying,Tang Lulin,Shang Wenbin.The role of epigenetic modification in the pathogenesis of autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(04):169.[doi:10.3760/cma.j.issn.1673-4157.2020.03.006]
[6]梁杏燕,赵捷,马红霞.自身免疫性甲状腺疾病对多囊卵巢综合征不良妊娠结局的影响[J].国际内分泌代谢杂志,2022,42(06):481.[doi:10.3760/cma.j.cn121383-20211016-10036]
　Liang Xingyan,Zhao Jie,Ma Hongxia..Influence of autoimmune thyroid disease on adverse pregnant outcome in polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2022,42(04):481.[doi:10.3760/cma.j.cn121383-20211016-10036]

备注/Memo

备注/Memo:
通信作者:朱梅,Email:meichuqin@163.com
更新日期/Last Update: 2016-09-20